August 13, 2007
AnGes MG, Inc.

AnGes MG, Inc. Submits BLA for Naglazyme in Japan

AnGes MG, Inc. (AnGes) announced today that, the company has submitted a Biologics License Application (BLA) for Naglazyme (galsulfase) to the Ministry of Health, Labour and Welfare in Japan.

AnGes established a marketing and distribution agreement with BioMarin Pharmaceutical Inc. (BioMarin) in December 2006, through which AnGes obtained exclusive rights to market Naglazyme in the Japanese market.
"We are pleased to announce the submission BLA for Naglazyme through the collaboration with BioMarin, and hope that Naglazyme will be launched in Japan and used by the patients at the earliest possible date," said Ei Yamada, Chief Executive Officer at AnGes.
"We are pleased to be working with AnGes to bring the first treatment option to MPS VI patients in Japan," said Stephen Aselage, Senior Vice President of Global Commercial Development at BioMarin. "Patient advocacy groups and medical societies in Japan have shown a strong interest in Naglazyme, and we are honored to bring this life-altering therapy to MPS VI patients in the U.S., Europe, and now to other parts of the world."

Naglazyme was approved by the U.S. Food and Drug Administration (FDA) in May 2005 and by the European Commission (EC) in January 2006. As the first drug approved for MPS VI, the FDA and EC have both designated Naglazyme as an orphan drug, conferring seven years of market exclusivity in the United States and 10 years of market exclusivity in the European Union. In addition, Naglazyme obtained orphan designation in June 2007 from the Ministry of Health, Labour and Welfare (MHLW) in Japan.

About MPS VI

MPS VI (also known as Maroteaux-Lamy syndrome) is a debilitating, life-threatening genetic disease caused by a deficiency of the enzyme N-acetylgalactosamine 4-sulfatase. This enzyme deficiency leads to the accumulation of certain complex carbohydrates, glycosaminoglycans (GAGs), in the lysosomes, giving rise to progressive cellular, tissue and organ system dysfunction. The majority of individuals with MPS VI die from

disease-related complications between childhood and early adulthood. Additional information can be found at www.mpsvi.com.

About Naglazyme

Naglazyme is the first and only enzyme replacement therapy indicated for the treatment of MPS VI. As the first drug approved for MPS VI, regulatory agencies in both the United States and European Union have granted Naglazyme orphan drug status, which confers seven years and 10 years of market exclusivity, respectively. Additional information can be found at www.naglazyme.com.

Naglazyme is indicated for patients with MPS VI. Naglazyme has been shown to improve walking and stair-climbing capacity.

The most common adverse events observed in clinical trials in Naglazyme-treated patients were headache, fever, arthralgia, vomiting, upper respiratory infections, abdominal pain, diarrhea, ear pain, cough, and otitis media. Severe reactions included angioneurotic edema, hypotension, dyspnea, bronchospasm, respiratory distress, apnea, and urticaria. The most common symptoms of infusion reactions included fever, chills/rigors, headache, rash, and mild to moderate urticaria. Nausea, vomiting, elevated blood pressure, retrosternal pain, abdominal pain, malaise, and joint pain were also reported. No patients discontinued Naglazyme infusions for adverse events and all patients that completed the double-blind portion of the trial continue to receive weekly infusions of Naglazyme. Nearly all patients developed antibodies as a result of treatment, but the level of the immune response did not correlate with the severity of adverse events or impact the improvements experienced in endurance. Because antihistamine use may increase the risk of apneic episodes, evaluation of airway patency should be considered prior to the initiation of treatment. Consideration to delay Naglazyme infusion should be given when treating patients who present with an acute febrile or respiratory illness.

About BioMarin Pharmaceutical Inc.

Head quarter : 105 Digital Drive, Novato, CA 94949, U.S.A.
CEO : Jean-Jacques Bienaimé
Founded : 1997
Number of employees : 460 (as of July 2007)

Business : Manufacture, develop and commercialize drugs.

Marketed Products :

- Naglazyme® (galsulfase) for MPS VI
- Aldurazyme® (laronidase) for MPS I